Shanmuga Hospital Limited profit rises 60% to Rs 1.70 crore

Shanmuga Hospital Limited reported standalone profit after tax of Rs 1.70 crore for the quarter ended 30th September, 2026, up 60% from Rs 1.06 crore a year earlier, as revenue from operations rose 2.6% and cost of consumption fell 20.4%. Profit before tax increased to Rs 2.30 crore from Rs 1.40 crore.

Why did Shanmuga Hospital's September-quarter profit rise?

Shanmuga Hospital's profit rose as a modest increase in operating revenue coincided with a decline in total expenses. Revenue from operations reached Rs 13.48 crore in the quarter ended 30th September, 2026, compared with Rs 13.14 crore in the quarter ended 30th September, 2025. Other income increased to Rs 13.29 lakh from Rs 0.21 lakh, taking total income to Rs 13.62 crore from Rs 13.14 crore.

Total expenses declined 3.6% to Rs 11.31 crore from Rs 11.74 crore, while profit before tax increased to Rs 2.30 crore from Rs 1.40 crore. Current tax rose to Rs 44.72 lakh from Rs 23.46 lakh and deferred tax increased to Rs 15.69 lakh from Rs 10.81 lakh, but profit after tax reached Rs 1.70 crore. The filing reported no exceptional or extraordinary items for either September quarter.

Which costs changed in Shanmuga Hospital's September quarter?

The largest year-on-year expense reduction was in cost of consumption, which fell to Rs 3.44 crore in the September 2026 quarter from Rs 4.32 crore a year earlier. The Rs 88 lakh decline exceeded the increases in several other cost lines and accompanied the reduction in total expenses from Rs 11.74 crore to Rs 11.31 crore.

Employee benefits expense increased to Rs 2.28 crore from Rs 2.26 crore, while other expenses rose to Rs 4.76 crore from Rs 4.12 crore. Finance costs declined to Rs 7.86 lakh from Rs 14.11 lakh, and depreciation and amortisation expenses fell to Rs 76.35 lakh from Rs 89.47 lakh. These three movements, together with the consumption-cost reduction, were recorded in the September-quarter results.

On a sequential basis, revenue from operations increased from Rs 11.87 crore in the quarter ended 30th June, 2026 to Rs 13.48 crore in the September quarter. Profit after tax rose from Rs 98.65 lakh to Rs 1.70 crore over the same period, while total expenses increased from Rs 10.59 crore to Rs 11.31 crore. The sequential comparison therefore includes both higher revenue and higher expenses.

How did Shanmuga Hospital perform in the half year ended September 2026?

Shanmuga Hospital reported profit after tax of Rs 2.69 crore for the half year ended 30th September, 2026, up 33.5% from Rs 2.01 crore in the corresponding half year ended 30th September, 2025. Revenue from operations increased 3.0% to Rs 25.35 crore from Rs 24.62 crore, while total income rose to Rs 25.53 crore from Rs 24.72 crore.

Total expenses for the half year edged down to Rs 21.91 crore from Rs 22.02 crore, producing profit before tax of Rs 3.62 crore compared with Rs 2.70 crore a year earlier. Cost of consumption declined to Rs 6.12 crore from Rs 8.13 crore, whereas employee benefits expense increased to Rs 4.49 crore from Rs 3.67 crore and other expenses rose to Rs 9.62 crore from Rs 8.28 crore.

Basic and diluted earnings per share, which Shanmuga Hospital said were not annualised, were Rs 1.97 for the half year ended 30th September, 2026, against Rs 1.48 a year earlier. For the September quarter, basic and diluted earnings per share were Rs 1.25, compared with Rs 0.78 in the September 2025 quarter. The results used a weighted average of 1,36,13,000 equity shares in each reported period.

What do Shanmuga Hospital's balance sheet and cash flow show?

Shanmuga Hospital's total assets were Rs 54.03 crore at 30th September, 2026, compared with Rs 53.06 crore at 31st March, 2026. Trade receivables increased to Rs 8.03 crore from Rs 6.86 crore, while cash and cash equivalents rose to Rs 2.47 crore from Rs 1.93 crore. Property, plant and equipment decreased to Rs 36.76 crore from Rs 37.47 crore, while capital work-in-progress increased to Rs 2.60 crore from Rs 2.44 crore.

Short-term borrowings declined to Rs 1.95 crore at 30th September from Rs 3.14 crore at 31st March, while long-term borrowings were unchanged at Rs 3.59 crore. Reserves and surplus increased to Rs 31.57 crore from Rs 28.89 crore. Trade payables to creditors other than micro enterprises and small enterprises fell to Rs 1.45 crore from Rs 2.06 crore.

Net cash from operating activities was Rs 2.53 crore in the half year ended 30th September, 2026. The increase in trade receivables used Rs 1.17 crore of cash, while purchases of property, plant and equipment used Rs 92.98 lakh. Repayment of short-term borrowings used Rs 1.19 crore, leaving a net increase in cash and cash equivalents of Rs 54.01 lakh for the half year.

How were Shanmuga Hospital's September results reviewed?

Shanmuga Hospital's audit committee and board approved the unaudited standalone results on 12th November, 2026. The results were prepared under Accounting Standards prescribed under the Companies Act, 2013. The filing states that companies listed on the SME Exchange are exempt from the compulsory adoption of Indian Accounting Standards, or Ind AS, under the cited Ministry of Corporate Affairs notification.

P PN and Company conducted a limited review of the half-year standalone results and stated that nothing had come to its attention to suggest that the statement lacked required disclosures or contained a material misstatement. Shanmuga Hospital reported one business segment and said it had no subsidiary, associate or joint venture for the reported period, making segment disclosure inapplicable.

Conclusion

Shanmuga Hospital combined 2.6% growth in September-quarter revenue from operations with a 20.4% reduction in consumption costs, lifting profit after tax by 60% to Rs 1.70 crore. For the half year ended September 2026, profit after tax rose 33.5% to Rs 2.69 crore, while trade receivables increased to Rs 8.03 crore and operating cash flow was Rs 2.53 crore.

The next disclosed corporate event is the re-appointment of Dr. Palaniappan Shanmugam Panneerselvam as managing director for five years from 16th February, 2027 to 15th February, 2032. The filing does not set a financial target or operating plan, so subsequent results will indicate whether the reported expense, receivables and cash-flow movements continue.